Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer

Schorge, John O.; Wingo, Shana N.; Bhore, Rafia; Heffernan, Thomas P.; Lea, Jayanthi S.

doi:10.1016/j.ijgo.2009.08.034

« Previous Next »International Journal of Gynecology & Obstetrics
Volume 108, Issue 2 , Pages 123-127, February 2010

Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer☆

John O. Schorge
- Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
- Corresponding author. Division of Gynecologic Oncology, Massachusetts General Hospital, Yawkey Center-9E, 55 Fruit Street, Boston, MA 02114, USA. Tel.: +1 617 724 4800; fax: +1 617 724 6898.
Shana N. Wingo
- Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Rafia Bhore
- Division of Biostatistics, Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Thomas P. Heffernan
- Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Jayanthi S. Lea
- Division of Gynecologic Oncology, Carolinas Medical Center, Charlotte, North Carolina, USA

Received 19 May 2009; received in revised form 12 August 2009; accepted 23 September 2009. published online 05 November 2009.

Abstract

Objective

To determine the risks and benefits of secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer.

Methods

Data were obtained retrospectively for all women with recurrent platinum-sensitive epithelial ovarian cancer who underwent a second debulking operation between 1998 and 2008 at the University of Texas Southwestern Medical Center. Survival analysis and comparisons were performed using the Kaplan-Meier method, log-rank test, and Cox multivariate proportional hazards model.

Results

Optimal secondary cytoreductive surgery (<5mm of residual disease) was achieved in 32 of 40 patients (80%). Nine women (23%) developed major complications. Two variables, residual disease of less than 5mm vs 5mm or greater (median 63months vs 11months; P=0.003); and less than 5 vs 5 or more sites of disease relapse (median 63months vs 22months; P=0.009), were independently associated with survival and retained prognostic significance on multivariate analysis.